Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Miami’s luxury condo market has many success stories, but few rise to the level of Maile Aguila. After closing more than $1 billion in sales in 2024, Aguila has become one of the most influential forces in Brickell and downtown Miami. From her beginnings in accounting to becoming the go‑to expert for high‑end developments, her journey offers a blueprint for new agents: specialize, become hyper‑local, master the soft sell, and make yourself indispensable. Her story shows that passion, knowledge, and relentless learning are the keys to breaking into Miami’s booming luxury market.
Former NFL defensive tackle Kendal Vickers has traded stadium lights for property listings, launching a fast-rising real estate career after earning licenses in both Florida and Tennessee. Drawing on his construction background and the discipline he built in the league, Vickers quickly closed early deals and now leads sales for two major residential developments. Motivated by helping families find homes, he’s proving that with grit, education, and the right mindset, a powerful second act is possible—on or off the field.
A shifting housing market and evolving regulations are making title insurance more critical than ever in 2026. Cortes and Hay, a New Jersey title agency with over 50 years of experience, breaks down the essential factors every buyer and investor should understand—from the importance of thorough title searches to the growing need for investor protection, ALTA best practices, and expert guidance on 1031 exchanges. This updated snapshot helps consumers and future real estate professionals navigate today’s complex closing landscape with confidence.
Nearly half of today’s homebuyers expect to use AI in their buying journey, and Florida is becoming a leading testing ground. New platforms like Homa are automating most of the homebuying process, delivering major savings to buyers while still blending in human expertise. As both tech-driven tools and traditional agents adapt, the future of Florida real estate will rely on professionals who can combine smart technology with real-world experience.
Florida’s once‑red‑hot investment market is cooling fast, with cities like Orlando, Fort Lauderdale, and Jacksonville seeing steep drops in investor purchases. Rising insurance costs, swelling inventory, and squeezed profit margins are pushing investors to pause—or look elsewhere. But West Palm Beach stands apart, surging with luxury demand as it cements its status as “Wall Street South.”
With mortgage rates nearly a full point lower than last year and inventory slowly rising, 2026 is opening the door for more buyers to re-enter the market. Competition has cooled, bidding wars have eased, and sellers are more flexible than they’ve been in years. While winter weather temporarily slowed sales, spring is expected to bring renewed momentum. For buyers with steady finances and long‑term plans, this year may offer one of the most balanced markets since the frenzy of 2021–2022.
